

Global

DowJones Nasdaq

Nikkei 225

FTSE 100

Shanghai

Hang Seng

Straits Times

DAX

MSEARCH

Dated: 17 February 2020

MORNING NEWSLETTER

Indices	СМР	%1D
Sensex	41258	-0.49
Nifty	12113	-0.50
BSE-Midcap	15662	-0.79
BSE-Smallcap	14682	-0.40
SGX Nifty	12124	-0.05

Market Outlook

Indian markets indicates for a possible negative opening on the back of weak domestic and global cues. While Global markets are still worried on increasing risk of Coronavirus status which remains a key monitorable for the markets over the next few days. Uncertainties surrounding the virus would downbeat economic and damper investors sentiments. Back to domestic markets technically the key support level for Nifty is placed at 12,054 followed by 11,994. If the index continues moving up, key resistance levels to watch out for are 12,209 and 12,307.

Index	FY20	FY21E	FY22E
Sensex EPS	1402	1985	2244
P/E	29	20	18
Nifty EPS	458	603	688
P/E	26	20	17

Current

Value

29399

9731

13744

23537

7409

27998

2947

3220

%1D

-0.08

0.20

-0.01

-0.64

-0.58

0.66

1.04

-0.01

Top Domestic News

- January Trade Deficit at USD 15.17 billion, Imports at USD 41.14 billion & Exports at USD 25.97 billion
- · Granules India: USFDA completes inspection at company's Hyderabad unit with 2 observations
- Cipla gets USFDA nod for Deferasirox CNBC-TV18
- Alkem Labs gets USFDA nod for Hypertension Drug Chlorthalidon CNBC-TV18
- Dr Reddy's Laboratories USFDA determines Duvvada's formulations manufacturing unit as voluntary action initiated (VAI)
- RITES emerges as successful bidder for supply of locomotives, coaches worth Rs 680 crore
- Hero MotoCorp launches BS-VI Splendor+, price starting Rs 59,600
- Dr Reddy's: US FDA completes audit of Srikakulum plant, with zero observation
- Zydus Cadila launches a fast tracked programme to develop vaccine for the novel coronavirus, 2019-nCoV (COVID-19)
- PNC Infratech Credit Analysis & Research Limited (CARE) assigned CARE AA; Stable rating to subsidiary, PNC Raebareli Highways, long term bank facilities of Rs 490.89 crore
- Punjab & Sind Bank revised the Marginal Cost of Fund Based Lending Rate (MCLR) for different tenors effective from 16.02.2020
- · Indiabulls Housing Finance CARE Ratings has revised the long-term rating to "CARE AA" with Stable outlook
- Lupin launches bacterial conjunctivitis drug Moxifloxacin Ophthalmic solution
- SAIL Q3: Consolidated net loss at Rs 343.6 crore versus profit at Rs 638.8 crore, revenue up 4.4 percent at Rs 16,542.5 crore versus Rs 15,842.2 crore, YoY
- Glenmark Pharma Q3: Consolidated net profit up 64.1 percent at Rs 190.8 crore versus Rs 116.3 crore, revenue up 7.1 percent at Rs 2,735.5 crore versus Rs 2,555 crore, YoY
- ONGC Q3: Net profit down 33.7 percent at Rs 4,151.6 crore versus Rs 6,263.1 crore, revenue down 3.2 percent at Rs 23,710 crore versus Rs 24,492.6 crore, QoQ
- Sun TV Q3: Net profit up 6.3 percent at Rs 373.5 crore versus Rs 351 crore, revenue down 9.9 percent at Rs 815 crore versus Rs 904 crore, YoY
- SREI Infra Q3: Consolidated net Profit down 34.4 percent at Rs 60.03 crore versus Rs 91.56 crore, revenue down 10.03 percent at Rs 1,450.5 crore versus Rs 1,617.5 crore
- IRB Infra Q3: Net profit down 27 percent at Rs 159.7 crore versus Rs 218.9 crore, revenue down 2.6 percent at Rs 1,742.6 crore versus Rs 1,788.5 crore, YoY

Trading activity in cash Rs Cr			
Date 14 Feb	Net	MTD	FY20
FII	-705	-2177	-12086
DII	220	1221	57304

Global News

Wall Street edged lower on Friday as uncertainties surrounding the coronavirus epidemic and downbeat economic data put a damper on investor sentiment. The Dow Jones Industrial Average fell 126.31 points, or 0.43%, to 29,297, the S&P 500 lost 5.97 points, or 0.18%, to 3,367.97 and the Nasdaq Composite dropped 14.85 points, or 0.15%, to 9,697.12. Asian shares stepped back from three-week highs on Monday as investors weighed the near-term hit on global growth from a fast-spreading coronavirus outbreak in China, although expectations of further policy stimulus helped stem losses.

I OI EX INALE		
USD/INR	71.39	0.07%
EUR/INR	77.51	-0.25%
GBP/INR	93.06	0.36%
JPY/INR	65.10	-0.02%

Corporate Action		
Stock Name	Purpose	Ex Date
AUROPHARMA	Interim Div Rs 1.75	17-Feb
GAIL	Interim Div Rs 6.40	17-Feb
RITES	Interim Div Rs 4	17-Feb
SUNPHARMA	Interim Div Rs 3	17-Feb
CONCOR	Interim Div Rs 0.75	17-Feb

G-Sec Yield	Price	Change%
1yr Bond Yield	5.32	-0.37%
10yr Bond Yield	6.37	-0.78%

Results Calender	17-Feb-20
ECI	

F&O Ban List YESBANK



Disclaimer: Investments in securities market are subject to market risks, read all the related documents carefully before investing.

Mehta Equities Limited (MEL) has used information that is publically available and information developed in-house. Some of the information used in the document may have been obtained from members/persons other than the MEL and/or its affiliates and which may have been made available to MEL and/or its affiliates. MEL however does not warrant the accuracy, reasonableness and/or completeness of any information and does not take responsibility of updating any data/information. For data reference to any third party in this material, no such party will assume any liability for the same. All data/information used in preparation of this material is dated and may or may not be relevant at any time after the issuance of this material. MEL (including its affiliates) and any of its officers, directors, personnel and employees, shall not be liable for any loss, damage of any nature, including but not limited to direct, indirect, punitive, special, exemplary, consequential, as also any loss of profit in any arising form the use of this material in any manner. Nothing contained in this document shall be construed to be an investment advice/recommendation on an assurance of the benefits of investing. Recipient alone shall be fully responsible for any investment decision taken on the basis of this document.

MEHTA EQUITIES LTD

BSE: - Membership Clearing No. 122 - SEBI Regn. No. INB010683856, NSE: - Membership Clearing No. 13512- SEBI Regn. No. INB231351231, NSE FO SEBI Regn. No. INF231351231, CIN No: U65990MH1994PLC078478

MSEI: - Membership Clearing No. 51800 - SEBI Regn. No. INB261351234

Mehta Equities Limited, 903, 9th floor, Lodha Supremus, Dr.E. Moses Road, Worli Naka, Worli, Mumbai 400 018, India

Tel: +91 22 6150 7101, Fax: +91 22 6150 7102

Email: info@mehtagroup.in Website: www.mehtagroup.in